Novo Nordisk Is Reducing Prices for Wegovy and Ozempic — What Actually Changes in the UK?

What has Novo Nordisk actually said, and does it apply in the UK?

Novo Nordisk has made pricing commitments in several markets, most prominently in the United States, where semaglutide medicines are priced very differently from their UK equivalents. The company's announcements have been directed at specific payers, insurers and government programmes in those regions. They are not a blanket global price cut that flows automatically to UK private patients.

In the UK, private prices for Wegovy are set by pharmacies and clinics, not by the manufacturer's list price alone. Supply costs, dispensing fees, clinical oversight, prescriber time and aftercare are all folded in. As widely reported following changes to Eli Lilly's UK pricing in late 2025, the private weight-loss injection market has seen price movement, but Wegovy's private pricing has followed its own trajectory. For a fuller picture of where UK private costs currently sit, our Wegovy pricing guide sets it out honestly, with the context you actually need.

The honest summary: if you have seen a headline about Novo Nordisk cutting the price of Wegovy, it is worth reading which market and which product that applies to. UK private prices for Wegovy have not fallen sharply as a result of those announcements, and anyone telling you otherwise is either mistaken or selling something.

Why do Wegovy and Ozempic cost different amounts, and which one is right for weight loss?

This is a question our prescribers hear most weeks, and the confusion is understandable. Both medicines contain semaglutide. But their licences in the UK are entirely separate. Wegovy is licensed for weight management in adults with a BMI of 30 or above, or 27 or above with at least one weight-related health condition. Ozempic is licensed for type 2 diabetes. Prescribing Ozempic for weight loss in someone without diabetes would be off-label, and the cost comparison between them is therefore not a straightforward consumer choice, it is a clinical one.

The NHS reflects this distinction precisely. Wegovy is available through specialist weight management services under NICE guidance (NICE technology appraisal TA875), while Ozempic is prescribed for diabetes management. Accessing either for weight loss through a private service requires a clinical assessment confirming the right medicine for your situation. The pricing on any given listing reflects only part of what you are actually paying for, the clinical infrastructure around it matters at least as much.

You can explore how the costs for each compare across different private providers on our Ozempic injection pricing page, which addresses what these medicines actually cost and why.

What does a legitimate UK private price for Wegovy include, and what is often left out?

Private pricing for Wegovy varies between providers, and headline figures can be misleading. Some prices cover the pen only, with consultation fees charged separately. Others add a prescription fee on top, or bill for aftercare, dose reviews or delivery. A quoted monthly cost that looks competitive can climb meaningfully once those extras are added.

For a thorough breakdown of what goes into a month's supply at different dose stages, our monthly Wegovy cost guide walks through the full picture. It also covers what affects the price as doses increase, something that catches many patients off guard after their first pen.

At nume, the price we show is the price you pay. Consultation, prescription, the treatment itself, next-working-day tracked delivery and 7-day aftercare are all part of it. We are not the cheapest option in the market. That is a deliberate choice: the infrastructure that keeps prescribing safe (identity verification, live weight checks, GP notification, clinical re-review before every repeat) costs something to do properly. You can see what is included and what treatment costs on our treatments page.

For weight loss in the UK: what is actually licensed, and where can you get it?

Given that price announcements often lump Wegovy and Ozempic together when reporting cuts, it is worth being clear about what the UK regulatory position actually is. For weight management, two medicines hold a UK licence: Wegovy (semaglutide injection, and now also in tablet form) and Mounjaro (tirzepatide). Ozempic is not licensed for weight loss in the UK, as the NHS semaglutide medicines guidance makes clear. A prescriber cannot legally and appropriately prescribe it for that purpose through a regulated UK service.

If you are researching weight management options and have arrived here via the Novo Nordisk price news, the practical next step is a clinical assessment for a medicine that is actually licensed for what you need. Our weight loss treatment overview explains how Wegovy and the other licensed options compare, and what the consultation process looks like. The prescribers on our team (you can read more about our clinical oversight on the clinical team page) assess every case individually. Price is a fair thing to factor in. It just should not be the only thing.